PTSM: Pharmaceutical Technology Sourcing and Management
Despite the benefits of continuous processing adoption has been slow, except for a few process areas.
Kathleen A. Estes
Advertisement
Kathleen A. Estes, PhD, is director of research communications atBioPlan Associates, Inc. She is an experienced market research and data trends analyst, author, and editor, [email protected].
Articles by Kathleen A. Estes
Although widespread adoption of continuous bioprocessing has been slow, some processes have been an exception.
Advertisement
Latest Updated Articles
Overcoming Concerns to Adopting Continuous ProcessesJuly 5th 2017
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why the First Generic Single-Dose Flu Antiviral Approval Matters
2
Germany Pharma Tariff Threat: What Manufacturers Need to Know
3
Why Pharma Dealmaking Slowed in Q1 2026 and What Is Coming Next
4
PharmTech Weekly Roundup—June 19, 2026
5